Age: 73.0
Sex: M
Vaccine: FLUX, RVX
Symptoms: Headache, Malaise, Pyrexia
Clinical narrative: Pyrexia; Headache; Sick; This non-serious case was reported by a consumer via other manufacturer and described the occurrence of low grade fever in a 73-year-old male patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis.   Co-suspect products included Influenza vaccine for prophylaxis and COVID-19 vaccine for prophylaxis.   Concurrent medical conditions included atopic dermatitis. Concomitant products included salbutamol (Albuterol), fluticasone propionate, dupilumab (Dupixent), fluconazole, fexofenadine hydrochloride (Allegra) and lorazepam.   On 20-SEP-2024, the patient received the 1st dose of RSV vaccine and the 1st dose of Influenza vaccine. In SEP-2024, the patient received the 1st dose of COVID-19 vaccine. In SEP-2024, an unknown time after receiving RSV vaccine and an unknown time after starting Albuterol and fluticasone propionate, the patient experienced low grade fever (Verbatim: Pyrexia), headache (Verbatim: Headache) and sickness (Verbatim: Sick). The outcome of the low grade fever, headache and sickness were resolved (duration 1 day).   It was unknown if the reporter considered the low grade fever, headache and sickness to be related to RSV vaccine.     It was unknown if the company considered the low grade fever, headache and sickness to be related to RSV vaccine.   Additional Information: GSK Receipt Date: 15-NOV-2024 The reporter reported that a 73-year-old male patient who had low grade fever and headache for 1 day while being treated with dupilumab, covid-19 vaccine, RSV (Respiratory Syncytial Virus) vaccine and influenza vaccine. The patient past medical history, medical treatment, vaccination, and family history were not provided.  Concomitant medications included Lorazepam; Fexofenadine hydrochloride (Allegra); Gabapentin; Salbutamol sulfate (Albuterol); Fluconazole and Fluticasone propionate.  On 25th March 2021, the patient started taking dupilumab solution for injection at a dose of 300mg subcutaneously via dupilumab pre-filled syringe for A topic dermatitis unspecified. On an unknown date in September 2024, the patient started taking Covid. 19 vaccine for COVID-19 immunization. On 20-Sep-2024, the patient started taking RSV vaccine and influenza vaccine for Influenza immunization. On an unknown date in September 2024, the patient developed a non-serious event of low-grade fever (Pyrexia)following the first dose intake of dupilumab and following the first dose intake of covid-19 vaccine, RSV vaccine and influenza vaccine.  On an unknown date in Sep-2024, the patient developed a non-serious event of headache for 1 day (headache) following the first dose intake of dupilumab and following the first dose intake of covid 19 vaccine, RSV vaccine and influenza vaccine.  Information regarding batch number and expiry date corresponding to the one at time of event occurrence was requested for dupilumab. It was reported the patient took Covid vaccine 2 weeks ago and the RSV/Flu shot. It made him sick. He had low grade fever and headache for 1 day. Patient received Flu/RSV vaccinations on 20th September 2024. He stated he had low grade fever and was out for the day. He was asking if he can take Dupixent dose. Pharmacist counseled yes. No interactions with and Dupixent not suppress immune systems. No further information reported.